Dyskinesias Clinical Trial
Official title:
A Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multiple Oral Dose Study to Assess the Efficacy, Safety and Tolerability of AQW051 in Reducing L-dopa Induced Dyskinesias in Parkinson's Patients With Moderate to Severe L-dopa Induced Dyskinesias
This study will assess the safety, tolerability and efficacy of AQW051 in treating moderate to severe L-dopa induced dyskinesias (movement disorders) in patients with Parkinson's disease.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00986414 -
Evaluation of the Efficacy and Safety of AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease
|
Phase 2 | |
| Terminated |
NCT03270189 -
Effect of the Visual Information Change in Functional Dystonia
|
N/A | |
| Completed |
NCT05044572 -
Comparison of Open Chain Kinetic Exercises and Forward Head Posture Correction in Type II Scapular Dyskinesia
|
N/A | |
| Suspended |
NCT04912115 -
Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced Dyskinesia
|
Phase 2 | |
| Recruiting |
NCT05116813 -
Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based Therapy
|
Phase 2/Phase 3 | |
| Completed |
NCT01385592 -
Evaluation of the Efficacy and Safety of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
|
Phase 2 | |
| Completed |
NCT01491932 -
Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
|
Phase 2 | |
| Completed |
NCT00086294 -
ACP-103 to Treat Parkinson's Disease
|
Phase 2 | |
| Completed |
NCT00360568 -
Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects
|
Phase 3 | |
| Recruiting |
NCT05317390 -
Clinical Validation of DystoniaNet Deep Learning Platform for Diagnosis of Isolated Dystonia
|
N/A | |
| Completed |
NCT03956979 -
A Study in Parkinson's Disease in Patients With Moderate to Severe Dyskinesia
|
Phase 2 | |
| Active, not recruiting |
NCT04453995 -
A Follow-up of the Influencing Factors of Dyskinesia in Patients With Parkinson's Disease
|
||
| Not yet recruiting |
NCT05516875 -
Open-Label Extension Study of ASTORIA
|
Phase 2 | |
| Terminated |
NCT02589340 -
Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced Dyskinesia
|
Phase 1 | |
| Completed |
NCT00076674 -
Levetiracetam Treatment of L-dopa Induced Dyskinesias
|
Phase 2 | |
| Completed |
NCT00888186 -
Different Dyskinesias in Parkinson's Disease and Their Relation to Levodopa Pharmacokinetics
|
Phase 4 | |
| Completed |
NCT00004576 -
Study of LY300164 for the Treatment of Parkinson's Disease
|
Phase 2 | |
| Completed |
NCT00036296 -
Effects of Talampanel on Patients With Advanced Parkinson's Disease
|
Phase 1/Phase 2 | |
| Completed |
NCT00363727 -
Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson's
|
Phase 3 | |
| Recruiting |
NCT04857359 -
Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy
|
Phase 2/Phase 3 |